GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT03491553
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Auckland, New Zealand
🇺🇸University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 21
- Registration Number
- NCT03472326
- Locations
- 🇿🇼
Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals, Harare, Zimbabwe
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 395
- Registration Number
- NCT03449446
- Locations
- 🇺🇸
Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 123
- Registration Number
- NCT03434353
- Locations
- 🇰🇷
Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT03417778
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd., Grafton, Auckland, New Zealand
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇩🇪APEX GmbH, Munich, Germany
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 86
- Registration Number
- NCT03405935
- Locations
- 🇧🇪
UZ Gent, Ghent, Belgium
🇫🇷Hopital Saint-Andre, Bordeaux, France
🇫🇷C.H.U. de Nantes - Hotel Dieu, Nantes, France
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT03349346
- Locations
- 🇮🇹
Infantile Regina Margherita Hospital, Torino, Italy
🇮🇹Istituto Giannina Gaslini, Genova, Italy
🇫🇷Centre Hospitalier Régional Universitaire de Lille, Lille, France
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT03301506
- Locations
- 🇺🇸
Arkansas Diagnostic Center, Little Rock, Arkansas, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03285711
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT03248479
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States